Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of baricitinib in pediatric juvenile idiopathic arthritis
2017-004471-31Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in juvenile idiopathic arthritis (JIA) and systemic juvenile idiopathic arthritis (SJIA), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-emergent adverse events, adverse events of special interest, serious adverse events. Started May 2019; status: active.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2017-004471-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004471-31.